The optimal reaction conditions for hemolytic assay of alternative complement pathway activity in mouse serum were investigated. A microtiter system was used, in which a number of 7.5 X 10(6) rabbit erythrocytes per test well appeared to be optimal. Rabbit erythrocytes were superior as target cells over erythrocytes from a number of other animal species. The optimal conditions were as follows: an incubation temperature of 39 degrees C, an ionic strength of about 200 mM, and a magnesium concentration of 2.5 mM. Incubation during 60 min was not sufficient for an end-point titration. Addition of 1 mg of zymosan A per test well, however, enhanced and accelerated the hemolytic activity of mouse serum via the alternative pathway resulting in a maximum value after 45 min. This, most probably, proceeded by a mechanism involving the formation of a zymosan-C5-convertase and bystander lysis of the target cells. In contrast to the normal alternative pathway assay the zymosan-potentiated test did, most probably, not involve natural antibodies. Cobra venom factor was more efficient in enhancing the sensitivity of the assay for the mouse alternative complement pathway than zymosan. This makes this factor very useful for testing C-poor body fluids.

Download full-text PDF

Source
http://dx.doi.org/10.1016/0022-1759(85)90134-6DOI Listing

Publication Analysis

Top Keywords

alternative complement
12
complement pathway
12
optimal reaction
8
reaction conditions
8
assay mouse
8
mouse alternative
8
activity mouse
8
mouse serum
8
rabbit erythrocytes
8
test well
8

Similar Publications

Artificial intelligence-based framework for early detection of heart disease using enhanced multilayer perceptron.

Front Artif Intell

January 2025

Department of Computer Science and Artificial Intelligence, College of Computing and Information Technology, University of Bisha, Bisha, Saudi Arabia.

Cardiac disease refers to diseases that affect the heart such as coronary artery diseases, arrhythmia and heart defects and is amongst the most difficult health conditions known to humanity. According to the WHO, heart disease is the foremost cause of mortality worldwide, causing an estimated 17.8 million deaths every year it consumes a significant amount of time as well as effort to figure out what is causing this, especially for medical specialists and doctors.

View Article and Find Full Text PDF

C3 glomerulopathy (C3G), a rare kidney disease caused by dysregulation of alternative pathway complement activation, is characterized by glomerular C3 deposition, proteinuria, crescentic glomerulonephritis, and renal failure. The anti-C5 monoclonal antibody (mAb) drug eculizumab has shown therapeutic effects in some but not all patients with C3G, and no approved therapy is currently available. Here, we developed and used a triple transgenic mouse model of fast progressing lethal C3G (FHm/mP-/-hFDKI/KI) to compare the therapeutic efficacy of a bifunctional anti-C5 mAb fused to a functional factor H (FH) fragment (short consensus repeat 1-5 [SCR1-5]) and the anti-C5 mAb itself.

View Article and Find Full Text PDF

Advanced Pain Management in Patients with Terminal Cancer.

Curr Med Chem

January 2025

Department of Surgery, School of Medicine, Nazarbayev University, 5/1 Kerey and Zhanibek khandar str., 020000, Astana, Kazakhstan.

Understanding and managing pain in patients with terminal cancer is a vital aspect of palliative care, aimed at relieving suffering and improving quality of life in the final stages of illness. Studies indicate that approximately 50% of patients with stage 4 cancer report moderate to severe pain, with a quarter experiencing severe cancer-related pain. Despite opioid prescriptions in 97% of cases, a significant portion of patients continues to suffer unresolved pain during the last week of life.

View Article and Find Full Text PDF

Assessing the feasibility of a spiritual healing intervention for adults with moderate depression: A pilot randomized controlled trial.

Complement Ther Med

January 2025

National Research Center of Complementary and Alternative Medicine (NAFKAM), Faculty of Health Science, Institute of Community Medicine, UiT The Arctic University of Norway, Hansine Hansensveg 19, 9037 Tromsø, Norway.

Background: Many individuals with depression explore complementary and alternative medicine, including spiritual healing. This pilot randomized controlled trial (RCT) aimed to assess the feasibility of a study that integrated spiritual healing with standard care versus standard care alone for adults with moderate depression.

Method: In this pilot RCT with two parallel groups, 28 adult patients with depression were randomized to receive either spiritual healing alongside usual care (n=14) or usual care alone (n=14).

View Article and Find Full Text PDF

Background: Biomarkers that predict disease activity and prognosis should be established for neuromyelitis optica spectrum disorders (NMOSD). In this study, we investigated the association between complement factors and the prognosis of NMOSD.

Methods: We validated laboratory parameters as potential prognostic factors in 34 patients with NMOSD (31 females and 3 males) whose serum was collected at the time of recurrence and who were subsequently followed-up for 3 years without the use of biologics.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!